(A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 1513
e
r
u
t
u
F
t
h
g
i
r
B
&
m o d is W
,
e
f i
L
n e e r g r evE
2023
INTERIM
REPORT
*
CONTENTS
List of Documents Available for Inspection
2
Financial Highlights
3
Section I
Important Notice and Definitions
5
Section II
Company Profile and Major Financial Indicators
11
Section III
Management Discussion and Analysis
16
Section IV
Corporate Governance
93
Section V
Environmental and Social Responsibility
98
Section VI
Major Events
132
Section VII
Changes In Equity and Shareholders
156
Section VIII
Information on Preferred Shares
167
Section IX
Information on Bonds
168
Section X
Financial Report
169
LIST OF DOCUMENTS AVAILABLE FOR INSPECTION
Full text of the 2023 Interim Report of the Company signed by the legal representative.
The unaudited financial report for the six months ended 30 June 2023 of the Company prepared in accordance with the China Accounting Standards for Business Enterprises, which has been signed and sealed by the person-in-charge of the Company, the person-in-charge of the Company's accounting work and the person-in-charge of the accounting department (the head of the accounting department).
The original copies of all documents and announcements of the Company which have been disclosed to the public on the website designated by the CSRC during the Reporting Period.
(IV)
The English and Chinese versions of the 2023 Interim Report of the Company published on the website of the
Hong Kong Exchanges and Clearing Limited.
2
Livzon Pharmaceutical Group Inc. Interim Report 2023
FINANCIAL HIGHLIGHTS
Major financial indicators (RMB in millions)
6.15%
Same Period
Last Year
6,302.57 6,689.92
Reporting Period
11.50%
4.52%
-13.96%
7.62%
1,426.39
1,423.37
1,017.55
1,134.57
1,046.42
1,093.71
1,227.31
1,322.57
Operating income
Net profit attributable
Net profit after
Net cash flow from
Total profit
to shareholders of
extraordinary gains or
operating activities
the Company
losses attributable to
shareholders of
the Company
Basic earnings per share (RMB/share)
11.93%
1.09
1.22
Diluted earnings per share (RMB/share)
Same Period
Last Year
11.93%
Reporting Period
1.09
1.22
Composition of operating income (RMB in millions)
4.45%
0.94%
Chemical drug preparations
297.99
62.70
1.70%
APIs and intermediates
113.41
Traditional Chinese
14.26%
medicine preparations
953.85
Biological products
Total Operating
Diagnostic reagents
and equipment
Income
52.02%
Others
1,781.67
6,689.92
3,480.29
26.63%
Livzon Pharmaceutical Group Inc. Interim Report 2023
3
FINANCIAL HIGHLIGHTS
PERFORMANCE FOR THE REPORTING PERIOD IN TERMS OF REVENUE FROM VARIOUS SECTORS
Unit: RMB in millions
Chemical drug preparations
-7.75%
1,761.50
1,625.05
2.71%
1,340.201,376.48
5.31%
2.11%
264.00
278.03
194.65
198.76
2022
2023
2022
2023
2022
2023
2022
2023
Gastroenterology
Gonadotropic
Psychiatry
Anti-infection
hormones
APIs and
Traditional Chinese
intermediates
medicine preparations
3.03%
1,729.34
1,781.67
953.85
94.42%
490.62
Biological products
5.93%
107.06 113.41
Diagnostic reagents
and equipment
-13.88%
346.04
297.99
2022
2023
2022
2023
2022
2023
2022
2023
4
Livzon Pharmaceutical Group Inc. Interim Report 2023
Attachments
Original Link
Original Document
Permalink
Disclaimer
Livzon Pharmaceutical Group Inc. published this content on 23 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 August 2023 09:53:03 UTC.
LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.
LIVZON PHARMACEUTICAL GROUP INC. 
